212 results about "Hyaluronidase" patented technology

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL- 13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL- 13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL- 13). Also described herein are compositions and combinations comprising an antibody or an antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL- 13, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The invention belongs to the technical field of medical biological materials, and particularly relates to a sodium hyaluronate gel regeneration filler for injection and a preparation method and application thereof.The sodium hyaluronate gel serves as a carrier to disperse acellular matrix particles, the sodium hyaluronate gel forms a micron-sized porous structure in the cross-linking process through a microbubbling technology, and the sodium hyaluronate gel is prepared into the sodium hyaluronate gel regeneration filler for injection and the preparation method and application of the sodium hyaluronate gel regeneration filler. A local cross-linked network is strengthened by combining a secondary cross-linking process, high elastic modulus is realized while the content of sodium hyaluronate is reduced, so that the porous structure has excellent instant filling and shaping capability and controllable degradation behavior, the porous structure can promote permeation of hyaluronidase, the degradation period of the hyaluronidase is matched with the tissue regeneration process, and the tissue regeneration effect is improved. And the acellular matrix particles can continuously induce adhesion, migration, proliferation and differentiation of endogenous cells of tissues, synergistically promote in-situ tissue regeneration, effectively reduce repeated injection requirements and reduce long-term complication risks, and have a good application prospect in soft tissue filling and repairing.

The invention relates to an enzyme response antibacterial carbon dot and a preparation method and application thereof.The carbon dot takes a copper-doped carbon dot as a core and is covalently grafted with a hyaluronic acid shell layer through amidation reaction to form a composite nano material Cu-CDs (at) HA, specifically, soluble copper salt and folic acid are subjected to a hydrothermal reaction to obtain the copper-doped carbon dot, carboxyl is activated through EDC / NHS in a buffer system, and the carbon dot is prepared. And performing grafting reaction with hyaluronic acid to obtain a target product. The hyaluronidase-containing antibacterial composition can be specifically degraded and release antibacterial components under the action of hyaluronidase, shows good bacterial responsive bactericidal performance, has the minimum inhibitory concentrations of 8 g / mL and 16 g / mL for staphylococcus aureus and escherichia coli respectively, and has peroxidase-like activity and free radical scavenging capacity. The antibacterial carbon dots can be used for preparing intelligent wound dressings, antibacterial coatings and other biomedical materials, and have the advantages of responsive drug release, efficient antibacterial property and promotion of wound repair.

The invention relates to the technical field of polypeptide detection, and particularly discloses a method for determining the content of human epidermal growth factors in sodium hyaluronate composite gel. The method comprises the following steps: S1, carrying out enzymolysis on sodium hyaluronate in the sodium hyaluronate composite gel by using an enzyme to obtain a test solution; s2, measuring a blank matrix solution containing no human epidermal growth factors, and adding enzyme for enzymolysis to obtain a blank matrix solution; s3, measuring the human epidermal growth factor, and diluting the human epidermal growth factor with the blank matrix solution to obtain a reference substance solution; and S4, detecting the test solution and the reference solution by using a high performance liquid chromatography and an ultraviolet detector, and determining the content of the human epidermal growth factor by using an external standard method. According to the method, hyaluronidase is used for pre-treating the test sample, macromolecular and high-viscosity sodium hyaluronate is subjected to enzymolysis to form micromolecular sugar, the method is compatible with the same liquid chromatography separation system, the content of the human epidermal growth factors in the test sample is measured by adopting an HPLC (High Performance Liquid Chromatography) combined ultraviolet detector, and the method is high in specificity, high in accuracy, low in detection limit and good in repeatability.

The present invention relates to a cartilage tissue single cell extraction kit and an extraction method thereof, the kit comprises: (1) a first enzyme for enzymatic hydrolysis, the first enzyme for enzymatic hydrolysis comprising one or more of trypsin, chondroitinase ABC and fucosidase; (2) a second enzyme for enzymolysis, wherein the second enzyme for enzymolysis comprises collagenase II, neutral protease II, hyaluronidase and Dnase I; and (3) a basic solution, wherein the basic solution comprises a basic culture medium and / or a buffer solution. The invention also provides a method for extracting single cells from cartilage tissues by using the kit. The cartilage tissue single-cell suspension prepared by the method has the advantages of high cell yield, high activity and the like, and has a wide application prospect.

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL-4Rα in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL-4Rα biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-4Rα antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL-4). Also described herein are compositions and combinations comprising an antibody or antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL-4Rα, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

The present invention is related to the field of protein engineering technology which increases the enzymatic activity and thermal stability of human hyaluronidase which is an enzyme that hydrolyzes hyaluronic acid; and more particularly to hyaluronidase PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions in the region corresponding to the alpha-helix region and / or its linker region in the amino acid sequence of wild-type PH20 of SEQ ID NO: 1 and in which one or more amino acid residues at the N-terminus and / or the C-terminus are selectively truncated additionally.Specifically, the present invention relates to PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions selected from the group consisting of T341A, T341C, T341G, S343E, M345T, K349E, L353A, L354I, N356E and I361T in wild-type PH20 having the amino acid sequence of SEQ ID NO: 1, and additionally comprise the substitution of amino acids located in the alpha-helix 8 region and / or a linker region between alpha-helix 7 and alpha-helix 8 in the amino acid sequence of wild-type PH20, and in which portion(s) of amino acids located at the N-terminal and C-terminal regions are deleted.

The invention discloses a composition with relieving and itching relieving effects as well as a preparation method and application thereof, and particularly belongs to the field of cosmetics. The composition comprises the following components: a composite plant extract, polyol and water, the composite plant extract is prepared by compounding a rhizoma polygonati fermentation liquid, a Chinese herbaceous peony extract and a caulerpa lentillifera extract; the rhizoma polygonati fermentation liquor is obtained by carrying out compound fermentation on lactobacillus pentosus and bacillus subtilis. The soothing and itching relieving composition provided by the invention has an excellent soothing effect, the soothing and itching relieving composition provided by the invention has an excellent in-vitro hyaluronidase inhibition effect, and the in-vitro hyaluronidase inhibition rate reaches 60% or above.

The invention discloses a tissue dissociation liquid, a tissue dissociation method and application thereof, and relates to the technical field of cell biology. In a DMEM / F12 culture medium, the tissue dissociation liquid only contains the following raw materials in concentration: 0.5 to 3 mg / mL of type II collagenase, 0.5 to 2 mg / mL of type IV collagenase, 0.5 to 2 mg / mL of hyaluronidase, 10 to 18 [mu] M of Y27632 and 80 to 150 [mu] g / mL of primocin. The tissue dissociation liquid provided by the invention can dissociate normal tissues or tumor tissues into single cells or cell clusters, the single cells obtained by the digestion method are high in proliferation rate and easy to successfully culture, and the tissue dissociation liquid has the technical advantages that the cell yield and survival rate are maintained at a relatively high level. Therefore, the tissue dissociation liquid provided by the invention has good application prospects in tumor tissue dissociation, cell line construction and organoid model construction.

Described herein are hyaluronidase particles, compositions comprising the same, and methods of making and using the same. The compositions of the invention may comprise hyaluronidase particles and may be a suspension. Granules comprising hyaluronidase may have a moisture content of less than about 15% by weight of the particle and / or a water activity of less than about 0.9. In some embodiments, the methods of the invention may comprise administering to a subject a particle comprising hyaluronidase subcutaneously, intramuscularly, and / or intradermally, where the particle has a moisture content of less than about 15% by weight of the particle and / or a water activity of less than about 0.9.

The present invention provides a composition for reducing or eliminating vascular occlusion caused by hyaluronic acid soft tissue dermal fillers. [Solution] This disclosure provides for compositions comprising hyaluronidase, apparatus for housing such compositions, and methods and uses of such compositions and apparatus for reducing or eliminating hyaluronic acid-induced blockages in one or more blood vessels supplying an individual's eye; methods and uses of such compositions and apparatus for reducing or inhibiting vascular occlusion of an individual's eye; and methods and uses of such compositions and apparatus for reducing or inhibiting hyaluronic acid-induced vision loss in an individual.

Provided herein is a hypervesiculating Escherichia coli Nissle (ΔECHy) bacterium engineered to produce outer membrane vesicles (OMVs), said OMVs packaging a fusion peptide including cytolysin A (ClyA) and hyaluronidase (Hy). Also provided are methods of remodeling a tumor, methods of treating cancer, and pharmaceutical compositions including the engineered ΔECHy bacterium.

This invention relates to the field of microbial technology, specifically to a *Lactobacillus plantarum* YYS-B1 strain with hyaluronidase inhibitory activity and its applications. *Lactobacillus plantarum* (… Lactiplantibacillus plants YYS-B1 was deposited at the China General Microbiological Culture Collection Center (CGMCC) on June 12, 2023, with accession number CGMCC No. 27599. This *Lactobacillus plantarum* YYS-B1 exhibits excellent acid and bile salt resistance, enabling it to successfully reach the intestines and exert its probiotic effects. It also demonstrates outstanding anti-allergic, anti-inflammatory, and antioxidant capabilities, specifically exhibiting high hyaluronidase inhibition, strong free radical scavenging ability, and a good inhibitory effect on inflammatory responses caused by allergies. Therefore, it has significant application value and can be used in the development of functional products.

The invention relates to the technical field of protein engineering, which improves the enzymatic activity of human hyaluronidase at neutral pH, the hyaluronidase is an enzyme for hydrolyzing hyaluronic acid, and relates to novel hyaluronidase variants or fragments thereof, the present invention relates to hyaluronidase Hyal1 comprising one or more amino acid residue substitutions in the enzymatically active region in the amino acid sequence of the native hyaluronidase Hyal1 of SEQ ID NO: 1 and in the vicinity thereof, and wherein amino acid residues that are selectively additionally truncated are present at the N-terminus and / or C-terminus.

The present invention relates to a microneedle structure and a composition thereof that can effectively deliver a drug locally or systemically within the body by penetrating the dermis layer through the transdermis without causing damage to the skin by including a biodegradable composition containing a drug and hyaluronidase.

This invention provides an extract of *Elaeocarpus yunnanensis* from Yunnan and its preparation method and application. The preparation method includes the following steps: (1) crushing *Elaeocarpus yunnanensis*, mixing it with an enzyme, and then using a solvent for negative pressure cavitation extraction to obtain a crude extract of *Elaeocarpus yunnanensis*; (2) adsorbing and eluting the crude extract of *Elaeocarpus yunnanensis* obtained in step (1) using a macroporous resin to obtain the *Elaeocarpus yunnanensis* extract. The method provided by this invention can effectively extract active substances from *Elaeocarpus yunnanensis*. The obtained *Elaeocarpus yunnanensis* extract has high geranium content, high total flavonoid content, good antioxidant effect, high hyaluronidase inhibitory activity, good anti-inflammatory effect, and high collagenase activity inhibition rate. The preparation method is economical and environmentally friendly, and the reagents used can be recycled and reused. It can be used as an active substance in health care products and cosmetics.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

The present invention relates to a method for producing an intact form of hyaluronidase, and more specifically, to a method for producing an intact form of hyaluronidase (PH20) by controlling the culture temperature or medium components of host cells expressing natural human recombinant hyaluronidase PH20. In the present invention, an intact form of hyaluronidase PH20, rather than a truncated form of hyaluronidase PH20, is produced with high purity by regulating a culture temperature, a medium type, an additive feed medium component, a dissolved oxygen concentration, a glucose concentration, and a pH in host cells expressing natural human recombinant hyaluronidase PH20. Therefore, the intact hyaluronidase PH20 produced by the method of the present invention possesses high specific activity, and thus can be effectively applied to various fields.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

The present invention relates to a freeze-dried injectable formulation comprising beta-nicotinamide mononucleotide, an injectable composition comprising same, and a preparation method therefor. In addition, the present invention relates to a pain relief injectable composition and a preparation method therefor, the composition comprising beta-nicotinamide mononucleotide and hyaluronidase, and having a pH of greater than 4 and 8 or less.

The application discloses a chimeric antigen receptor targeting CEA and a T cell containing the chimeric antigen receptor targeting CEA. The chimeric antigen receptor is composed of a nanobody recognizing a CEA antigen, an extracellular hinge region, a transmembrane region, an intracellular signal region, a self-cleavage polypeptide T2A and a hyaluronidase in sequence. The chimeric antigen receptor can efficiently recognize the CEA antigen, and CD28 and CD137 are used as a costimulatory signal region to activate T cells, thereby playing a cellular immune role, and specifically killing CEA-positive tumor cells, and thus having an important application prospect in the field of tumor cell immunotherapy.

The invention belongs to the technical field of cosmetics, and particularly relates to a soothing and repairing composition and application thereof. The soothing and repairing composition provided by the invention is prepared from the stephania tetrandra extract, the phoenix dactylifera fruit extract, the flower extract and the mirabilis jalapa extract through specific compatibility, and all the components generate a synergistic effect, so that the transdermal absorption of active ingredients can be remarkably enhanced; experimental data show that the composition can effectively improve the hyaluronidase inhibition rate and the TNF-alpha inhibition rate, and has excellent soothing and repairing effects; the preparation method of the composition is simple and convenient to operate and easy to realize industrial large-scale production, and has a good industrial application prospect; when the composition is applied to the essence, the TEWL value improvement rate and the a * value improvement rate of the essence can be remarkably improved, and the soothing and repairing effects are obvious; and human body patch test results of the essence show that the essence is mild and non-irritating, so that the composition disclosed by the invention has wide market application value in skin care products.

Described herein are compositions and combinations comprising an antibody or antigen binding fragment thereof that binds thymic stromal lymphopoietin (TSLP), an antibody or antigen binding fragment thereof that binds Interleukin-4 Receptor Alpha (IL-4Ra), and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

This invention discloses a multi-enzyme preparation for industrial cell dissociation, its usage method, and applications, belonging to the field of seed cell extraction technology for industrial meat culture. The invention employs a multi-enzyme preparation composed of component 1 and component 2; component 1 includes neutral protease, hyaluronidase, and elastase; component 2 includes matrix metalloproteinase, papain, and plasmin. The invention also discloses the preparation method and applications of the multi-enzyme preparation. The rational enzyme ratio and optimized treatment conditions of this invention help protect cell membrane integrity, maintain high cell activity, and significantly improve dissociation efficiency and cell recovery. The compound enzyme preparation is highly adaptable, applicable to various tissue types and dissociation requirements, and facilitates standardized and large-scale production. Combined with automated dissociation equipment, the compound enzyme preparation enables efficient and stable industrial operation, providing important technical support and broad application prospects for the cultured meat industry, tissue engineering, and cell therapy.

The invention discloses a fluorescent reagent composition for detecting hyaluronidase and application thereof, and is characterized in that the fluorescent reagent composition comprises a sodium hyaluronate or hyaluronic acid solution, a magnetic nano material Fe3O4NPs solution and a fluorescent nano material UCNPs solution, the detection of hyaluronidase comprises the following steps: adding a to-be-detected urine sample containing hyaluronidase into a sodium hyaluronate solution to degrade sodium hyaluronate; adding a fluorescent nano-material UCNPs solution into the reaction product, enabling the fluorescent nano-material UCNPs solution to generate electrostatic adsorption with the unhydrolyzed sodium hyaluronate, and outputting a fluorescent signal F0; adding a magnetic nano material Fe3O4NPs solution for magnetic separation, and taking supernate to measure a fluorescence signal F; calculating the concentration of hyaluronidase in the urine sample to be detected by taking F / F0 as an output signal; the kit has the advantages of high sensitivity, strong specificity, high accuracy and simplicity in operation, and is used for ultra-sensitive detection of the bladder cancer biomarker HAase.

The present application relates to the field of sodium hyaluronate preparation, in particular to a preparation method of low molecular weight sodium hyaluronate. Specifically comprising the following steps: stirring and dissolving macromolecular weight sodium hyaluronate powder into water at 45-60 DEG C to obtain a macromolecular weight sodium hyaluronate solution; cooling to 35-45 DEG C, adding a buffer solution and mixing uniformly, then adding papain and hyaluronidase with a mass ratio of (2-3):(3-6) for enzymatic reaction to obtain an enzymatic solution; adding sodium hydroxide solution to the enzymatic solution, adjusting pH to 7.5-9.0, heating to 80-90 DEG C for 20-40 minutes, then filtering to obtain a low molecular weight sodium hyaluronate solution; spray drying, and the process is simple, the conditions are mild, the product structure is not damaged, and the prepared low molecular weight sodium hyaluronate has high purity, uniform molecular weight distribution and good permeability.

The present invention relates to methods for preparing hyaluronidase and variants thereof. Specifically, the methods are capable of altering N-glycan levels under culture conditions, including controlled glucose concentration within the culture medium and reduced culture temperature and specified culture time, thereby increasing specific activity by 10% or more, and improving quality and yield.

The invention provides a plant composition with anti-oxidation and soothing effects as well as a preparation method and application thereof. The plant composition with the anti-oxidation and soothing effects comprises a lotus plumule extract, a radix gentianae extract and a radix scutellariae / ampelopsis grossedentata mixed extract. The invention creatively finds that the lotus plumule extract, the radix gentianae extract and the radix scutellariae / ampelopsis grossedentata mixed extract have a synergistic effect after being combined, and by integrating specific targets of the raw materials, the multi-target soothing and anti-oxidation effects of the composition are improved, which can be specifically reflected in the aspects of scavenging free radicals, inhibiting hyaluronidase, inhibiting inflammatory factors and the like.

The invention relates to the crossing field of biomedical and food technologies, and provides a method for preparing low-molecular-weight hyaluronic acid through high hydrostatic pressure assisted enzymolysis, which comprises the following steps: dissolving sodium hyaluronate by adopting an acetic acid / sodium acetate buffer system, and adding bovine testis-derived hyaluronidase under the condition that the pH value is 4.5-5.5; high hydrostatic pressure enzymolysis at the temperature of 30-45 DEG C, the static pressure of 50-200 MPa and pulse type pressurization is combined, two to three stages of tangential flow ultrafiltration external circulation separation are cooperatively operated, molecular weight distribution is dynamically regulated and controlled through a segmented interception and backflow strategy between first-stage and second-stage membranes, excessive shearing and chromaticity rising are inhibited while the molecular weight interval target and flux are met, and the separation efficiency is improved. At the end of 50-100 kDa, the area proportion is 55-95% or the distribution is continuously changed for two times as long as lt; and after 5%, deactivating enzyme, desalting and freeze-drying to obtain the product. The polydispersity index of the obtained product is 1.05-1.40, micro impurities and residues are strictly controlled, and the product is suitable for cosmetics, functional food and biomedical materials.